These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20398256)

  • 21. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.
    Ugurluer G; Ozsahin M
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1637-54. PubMed ID: 25134724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma.
    Oliveira-Silva RJ; Carolina de Carvalho A; de Souza Viana L; Carvalho AL; Reis RM
    Recent Pat Anticancer Drug Discov; 2016; 11(2):170-83. PubMed ID: 26955963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer.
    Lango MN; Shin DM; Grandis JR
    Curr Opin Oncol; 2001 May; 13(3):168-75. PubMed ID: 11307060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR-targeted therapies in the post-genomic era.
    Xu MJ; Johnson DE; Grandis JR
    Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current aspects of targeted therapy in head and neck tumors.
    Dietz A; Boehm A; Mozet C; Wichmann G; Giannis A
    Eur Arch Otorhinolaryngol; 2008 Jul; 265 Suppl 1():S3-12. PubMed ID: 18535834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current management of advanced non-small cell lung cancer: targeted therapy.
    Isobe T; Herbst RS; Onn A
    Semin Oncol; 2005 Jun; 32(3):315-28. PubMed ID: 15988686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignancies of the head and neck: the role for molecular targeted agents.
    Agulnik M
    Expert Opin Ther Targets; 2007 Feb; 11(2):207-17. PubMed ID: 17227235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.
    Donnadieu J; Lachaier E; Peria M; Saidak Z; Dakpe S; Ikoli JF; Chauffert B; Page C; Galmiche A
    BMC Cancer; 2016 Apr; 16():273. PubMed ID: 27085492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.
    Cruz JJ; Ocaña A; Del Barco E; Pandiella A
    Ann Oncol; 2007 Mar; 18(3):421-30. PubMed ID: 16873430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma.
    O-charoenrat P; Rhys-Evans PH; Modjtahedi H; Eccles SA
    Oral Oncol; 2002 Oct; 38(7):627-40. PubMed ID: 12167415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma.
    Egloff AM; Grandis J
    Expert Opin Ther Targets; 2006 Oct; 10(5):639-47. PubMed ID: 16981821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications.
    Schmitz S; Machiels JP
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1471-84. PubMed ID: 20836682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
    Pollock NI; Grandis JR
    Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari PM
    Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.